

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Last Update: May 13, 2025

A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).

ClinicalTrials.gov Identifier:

[NCT05126277](#)

Novartis Reference Number: CVAY736K12301

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) Ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN. This trial will evaluate the efficacy, safety, and tolerability of subcutaneous (s.c.) Ianalumab given every 4 weeks (q4w) or Ianalumab given every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN (ISN/RPS class III, IV active glomerulonephritis with or without co-existing class V features, or pure class V membranous). using the 2003 International Society for Nephrology (ISN)/Renal Pathology Society (RPS) criteria).

Condition

Lupus Nephritis

Phase

Phase3

Overall Status

Recruiting

Number of Participants

420

Start Date

Jul 14, 2022

Completion Date

Jul 15, 2030

Gender

All

Age(s)

18 Years - 100 Years (Adult, Older Adult)

Drug

ianalumab s.c. q12w

ianalumab s.c. q12w in addition to SoC

Drug

ianalumab s.c. q4w

ianalumab s.c. q4w in addition to SoC

Drug

placebo s.c.

placebo s.c. q4w in addition to SoC

Eligibility Criteria

Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:

- * Adult male and female participants aged 18 years or older at the time of screening
- * Weigh at least 35 kg at screening
- * Have a confirmed clinical diagnosis of SLE according to European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Systemic Lupus Erythematosus (SLE) classification criteria
- * Have a positive anti-nuclear antibody (ANA) test result; ANA titer $\geq 1:80$ at screening visit based on central or local laboratory result
- * Active LN at screening, as defined by meeting the 3 following criteria:
 - * Renal biopsy within 6 months prior to screening period indicating ISN/RPS class III or IV active glomerulonephritis with or without co-existing class V features, or pure class V membranous LN. If no biopsy was performed within 6 months prior to screening period, a biopsy will need to be performed during the screening period after having met all other inclusion/exclusion criteria.
 - * UPCr ≥ 1.0 g/g on 24h urine collection at Screening
 - * eGFR ≥ 25 mL/min/1.73 m². Participants with eGFR < 30 mL/min/1.73 m² require renal biopsy during the screening period showing sclerosis in $\leq 50\%$ of glomeruli
- * Newly diagnosed participants as well as pre-treated LN participants (including refractory cases) can be included, as long as they are currently on, or willing to initiate SoC induction therapy for LN using MPA
- * Induction therapy, as defined by treatment including both high dose corticosteroids and MPA, should be initiated prior to or on day of randomization
- * Anti-malarial treatment at stable dosing prior to randomization is strongly recommended, in the absence of contraindications
- * Participants on azathioprine treatment at Screening must be switched to MPA prior to randomization
- * Receipt of at least one dose of pulse methylprednisolone i.v. (250 - 1000 mg per day up to 3000 mg cumulative dose) or equivalent for treatment of current episode of active LN within 60 days prior randomization. Participant who cannot take the pulse i.v. corticosteroid therapy should directly start on 0.8-1.0 mg/day (max 80mg/day) oral predniso(lo)ne.

- * Able to communicate well with the Investigator to understand and comply with the requirements of the study

Exclusion Criteria:

Participants meeting any of the following criteria are not eligible for inclusion in this study:

- * Severe renal impairment as defined by i.) presence of oliguria (defined as a documented urine volume ≤ 400 mL/24 hrs) or ii.) End-Stage Renal Disease (ESRD) requiring dialysis or transplantation
- * Sclerosis in $\geq 50\%$ of glomeruli on renal biopsy
- * Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days or until the expected pharmacodynamic effect has returned to baseline. Use of certain Traditional Chinese Medicines
- * Prior use of ivalumab (ever); or prior use other B cell depleting therapy within 36 weeks prior to randomization or if therapy was administered ≤ 36 weeks prior to randomization, B cell count less than the lower limit of normal or patient's own baseline value prior to having received an earlier B cell-depleting therapy
- * Prior treatment with any of the following within 12 weeks prior to randomization
 - * Belimumab, telitacicept, abatacept, TNF- α mAb, immunoglobulins (i.v./s.c.) plasmapheresis
 - * Any other immuno-suppressants (i.v. or oral cyclophosphamide, calcineurin inhibitors, JAK inhibitors or other kinase inhibitors)
 - * Thalidomide treatment and/or methotrexate
 - * Combination of DMARDs
 - * Imidazole derivative (e.g., azathioprine, mizoribine) must be discontinued prior to starting treatment with MPA
 - * Receipt of more than 3000 mg i.v. pulse methylprednisolone (cumulative dose) within 12 weeks prior to randomization
 - * History of major organ transplant or hematopoietic stem cell/bone marrow transplant or are due to receive transplantation
 - * Any one of the following laboratory values at screening:
 - * Hemoglobin levels ≤ 8.0 g/dL (≤ 5 mmol/L), or ≤ 7.0 g/dL (≤ 4.3 mmol/L) if related to participant's SLE such as in active hemolytic anaemia
 - * Platelet count $\leq 25 \times 1000/\mu\text{L}$
 - * Absolute neutrophil count (ANC) $\leq 0.8 \times 1000/\mu\text{L}$
 - * Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection or history of recurrent clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.
 - * History of known intolerance/hypersensitivity to MPA, oral corticosteroids, or any component of the study drug(s) or its excipients
 - * Receipt of live/attenuated vaccine within a 4-week period prior to randomization
 - * History of primary or secondary immunodeficiency, including a positive HIV test result
 - * History of malignancy of any organ system (other than localized basal cell carcinoma or squamous cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
 - * Any surgical, medical (e.g., uncontrolled hypertension, heart failure or diabetes), psychiatric or additional physical condition that the Investigator feels may jeopardize the participants in case of participation in this study
 - * Chronic infection with hepatitis B (HBV) or hepatitis C (HCV). Positive serology for hepatitis B surface antigen (HBsAg) excludes the participant
 - * Evidence of active tuberculosis (TB) infection (after anti-TB treatment, participants with history of TB may become eligible according to national local guidelines)
 - * Pregnant or nursing (lactating) women

* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 6 months after stopping of investigational medication

* Sexually active male participants, who do not agree to use barrier protection during intercourse with women of child-bearing potential while taking study treatment

Other protocol -defined Inclusion/Exclusion may apply.

Argentina

Novartis Investigative Site

Recruiting

Ciudad Autonoma de Bs As,Buenos Aires,C1015abo,Argentina

Novartis Investigative Site

Recruiting

La Plata,Buenos Aires,B1900awt,Argentina

Novartis Investigative Site

Recruiting

Ciudad Autonoma de Buenos Aire,1426,Argentina

Novartis Investigative Site

Recruiting

Tucuman,4000,Argentina

Novartis Investigative Site

Recruiting

Caba,Buenos Aires,C1056abj,Argentina

Brazil

Novartis Investigative Site

Recruiting

Juiz de Fora,MG,36010 570,Brazil

Novartis Investigative Site

Recruiting

Pernambuco,Recife,50740-900,Brazil

Novartis Investigative Site

Recruiting

Porto Alegre,RS,90020-090,Brazil

Novartis Investigative Site

Recruiting

Porto Alegre,RS,90035-003,Brazil

Novartis Investigative Site

Recruiting

Salvador,BA,40150 150,Brazil

Novartis Investigative Site

Recruiting

Santo Andre,SP,09090-790,Brazil

Novartis Investigative Site

Recruiting

Vitoria,ES,29055 450,Brazil

Novartis Investigative Site

Recruiting

Belo Horizonte,MG,30150-221,Brazil

Canada

Novartis Investigative Site

Recruiting

London,Ontario,N6a 5w9,Canada

Novartis Investigative Site

Recruiting

Winnipeg,Manitoba,R3a 1r9,Canada

Novartis Investigative Site

Recruiting

Montreal,Quebec,H1t 2m4,Canada

Novartis Investigative Site

Recruiting

Toronto,Ontario,M5t 2s8,Canada

Novartis Investigative Site

Recruiting

Sherbrooke,Quebec,J1g 2e8,Canada

Novartis Investigative Site

Recruiting

Calgary,Alberta,T2n 4z6,Canada

Novartis Investigative Site

Recruiting

Etobicoke,Ontario,M9w 6v1,Canada

Novartis Investigative Site

Recruiting

Vancouver,British Columbia,V5z 1l7,Canada

Chile

Novartis Investigative Site

Recruiting

Santiago,RM,7500922,Chile

Novartis Investigative Site

Recruiting

Temuco,4790084,Chile

China

Novartis Investigative Site

Recruiting

Linyi,Shandong,276000,China

Novartis Investigative Site

Recruiting

Zhejiang,315016,China

Novartis Investigative Site

Recruiting

Hefei,Anhui,230022,China

Colombia**Novartis Investigative Site**

Recruiting

Medellin,Antioquia,050001,Colombia

Novartis Investigative Site

Recruiting

Bogota,Cundinamarca,110111,Colombia

Novartis Investigative Site

Recruiting

Barranquilla,080020,Colombia

Czechia**Novartis Investigative Site**

Recruiting

Olomouc,779 00,Czechia

Novartis Investigative Site

Recruiting

Praha 2,128 50,Czechia

Estonia**Novartis Investigative Site**

Recruiting

Tallinn,10138,Estonia

Novartis Investigative Site

Recruiting

Tallinn,10117,Estonia

France**Novartis Investigative Site**

Recruiting

Marseille,13385,France

Novartis Investigative Site

Recruiting

Angers Cedex 9,49933,France

Novartis Investigative Site

Recruiting

Poitiers,86021,France

Novartis Investigative Site

Recruiting

Besancon Cedex,25030,France

Novartis Investigative Site

Recruiting

Bordeaux Cedex,33076,France

Novartis Investigative Site

Recruiting

Grenoble,38043,France

Novartis Investigative Site

Recruiting

Lyon,69003,France

Germany**Novartis Investigative Site**

Recruiting

Aachen,52074,Germany

Novartis Investigative Site

Recruiting

Bochum,44791,Germany

Novartis Investigative Site

Recruiting

Muenster,48149,Germany

Guatemala

Novartis Investigative Site

Recruiting

Guatemala,01010,Guatemala

Novartis Investigative Site

Recruiting

Quetzaltenango,9001,Guatemala

Novartis Investigative Site

Recruiting

Guatemala City,01011,Guatemala

Hong Kong

Novartis Investigative Site

Recruiting

Kwun Tong,Kowloon,Hong Kong

Novartis Investigative Site

Recruiting

Tuen Mun,999077,Hong Kong

Hungary

Novartis Investigative Site

Recruiting

Debrecen,4032,Hungary

Novartis Investigative Site

Recruiting

Kaposvar,7400,Hungary

Novartis Investigative Site

Recruiting

Budapest,H-1032,Hungary

Novartis Investigative Site

Recruiting

Budapest,H-1097,Hungary

India

Novartis Investigative Site

Recruiting

Bangalore,Karnataka,560 079,India

Novartis Investigative Site

Recruiting

Secunderabad,Telangana,500003,India

Novartis Investigative Site

Recruiting

Lucknow,Uttar Pradesh,226014,India

Novartis Investigative Site

Recruiting

Chandigarh,160 012,India

Italy

Novartis Investigative Site

Recruiting

Udine,UD,33100,Italy

Novartis Investigative Site

Recruiting

Foggia,FG,71122,Italy

Novartis Investigative Site

Recruiting

Firenze,FI,50134,Italy

Novartis Investigative Site

Recruiting

Milano,MI,20132,Italy

Novartis Investigative Site

Recruiting

Pavia,PV,27100,Italy

Novartis Investigative Site

Recruiting

Roma,RM,00168,Italy

Novartis Investigative Site

Recruiting

Torino,TO,10154,Italy

Novartis Investigative Site

Recruiting

Cagliari,CA,09134,Italy

Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,04763,Korea, Republic of

Novartis Investigative Site

Recruiting

Bundang Gu,Gyeonggi Do,13620,Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,05030,Korea, Republic of

Novartis Investigative Site

Recruiting

Suwon si,Gyeonggi Do,16499,Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,05505,Korea, Republic of

Novartis Investigative Site

Recruiting

Busan,602 715,Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,06591,Korea, Republic of

Novartis Investigative Site

Recruiting

Daegu,705 718,Korea, Republic of

Novartis Investigative Site

Recruiting

Gwangju,61469,Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,03722,Korea, Republic of

Lithuania

Novartis Investigative Site

Novartis Investigative Site

Recruiting

Kaunas,LTU,Lt 50161,Lithuania

Novartis Investigative Site

Recruiting

Vilnius,Lt-08661,Lithuania

Malaysia

Novartis Investigative Site

Recruiting

Sibu,Sarawak,96000,Malaysia

Novartis Investigative Site

Recruiting

Kuala Terengganu,Terengganu,20400,Malaysia

Novartis Investigative Site

Recruiting

Kuala Lumpur,Wilayah Persekutuan,50586,Malaysia

Mexico

Novartis Investigative Site

Recruiting

Queretaro,76070,Mexico

Novartis Investigative Site

Recruiting

Leon,Guanajuato,37160,Mexico

Novartis Investigative Site

Recruiting

Monterrey,Nuevo Leon,64440,Mexico

Novartis Investigative Site

Recruiting

Oaxaca,68020,Mexico

Romania

Novartis Investigative Site

Recruiting

Oradea,Jud Bihor,410619,Romania

Novartis Investigative Site

Recruiting

Bucharest,022328,Romania

Novartis Investigative Site

Recruiting

Cluj Napoca,400006,Romania

Novartis Investigative Site

Recruiting

Bucuresti,011172,Romania

Novartis Investigative Site

Recruiting

Timisoara,300736,Romania

Singapore

Novartis Investigative Site

Recruiting

Singapore,169608,Singapore

Novartis Investigative Site

Recruiting

Singapore,S308433,Singapore

Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalunya,08003,Spain

Novartis Investigative Site

Recruiting

La Laguna,Santa Cruz De Tenerife,38320,Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalunya,08035,Spain

Novartis Investigative Site

Recruiting

Madrid,28040,Spain

Novartis Investigative Site

Recruiting

Valencia,Comunidad Valenciana,46017,Spain

Novartis Investigative Site

Recruiting

Madrid,28041,Spain

Novartis Investigative Site

Recruiting

Santiago De Compostela,Galicia,15706,Spain

Novartis Investigative Site

Recruiting

Madrid,280796,Spain

Novartis Investigative Site

Recruiting

Pamplona,Navarra,31008,Spain

Novartis Investigative Site

Recruiting

Vigo,Pontevedra,36200,Spain

Taiwan

Novartis Investigative Site

Recruiting

Taichung,407219,Taiwan

Novartis Investigative Site

Recruiting

Taipei,11217,Taiwan

Novartis Investigative Site

Recruiting

Kaohsiung,83301,Taiwan

Novartis Investigative Site

Recruiting

Taichung,40447,Taiwan

Thailand

Novartis Investigative Site

Recruiting

Chiang Mai,50200,Thailand

Novartis Investigative Site

Recruiting

Songkhla,Hat Yai,90110,Thailand

Novartis Investigative Site

Recruiting

Bangkok,10330,Thailand

Novartis Investigative Site

Recruiting

Bangkok,10400,Thailand

Novartis Investigative Site

Recruiting

Bangkok,10700,Thailand

United Kingdom

Novartis Investigative Site

Recruiting

Bradford,West Yorkshire,Bd9 6rj,United Kingdom

Novartis Investigative Site

Recruiting

London,Se1 9rt,United Kingdom

United States

James J Peters VA Medical Center

Recruiting

Bronx,New York,10468,United States

Chang Xu

Olga A Andriunas

Phone: [+17185849000#6667](tel:+17185849000#6667)

Email: olga.andriunas@va.gov

University of Texas Medical Branch

Recruiting

Galveston,Texas,77555-0144,United States

Stephanie Simmons

Phone: [409-772-1062](tel:409-772-1062)

Email: sttsimmo@utmb.edu

Tina Kochar

Kaiser Permanente

Recruiting

San Diego, California, 92111, United States

Jaqueline Gomez Solis

Phone: 858-401-7205

Email: Jaqueline.X.GomezSolis@kp.org

Hui Xue

Parris and Associates Rheumatology

Recruiting

Lawrenceville, Georgia, 30044, United States

Phone: +17709621616#8334

Glenn Parris

Circuit Clinical

Recruiting

Orchard Park, New York, 14127, United States

Isha Gupta

Uni of Texas Health Science Center

Recruiting

San Antonio, Texas, 78284, United States

Agustin Escalante

Phone: 210-617-5111

University of California LA

Recruiting

Los Angeles, California, 90095, United States

Maureen McMahon

Lori Sahakian

Phone: 310-825-9447

Email: LSahakian@mednet.ucla.edu

University Of Miami

Recruiting

Miami,Florida,33136,United States

Maria Fernanda Carpintero

Priscilla Madero

Phone: 305-243-2568

Email: pdm73@med.miami.edu

Univ of Nevada School of Med

Recruiting

Las Vegas,Nevada,89102,United States

Katherin Mendez

Email: katherin.mendez@unlv.edu

Walter Winn Chatham

Precision Comprehensive Research

Recruiting

Colleyville,Texas,76034,United States

Ashwin Boda

Phone: 972-299-8399

Email: ashwinboda@pccrsolutions.com

Dhiman Basu

Mayo Clinic Jacksonville

Recruiting

Jacksonville,Florida,32224,United States

Carolyn Stevens

Phone: 904-953-2451

Email: Thomas.Carolyn@mayo.edu

Nabeel Aslam

University Of Cincinnati

Recruiting

Cincinnati,Ohio,45267,United States

Leksi Travitz

Phone: [513-559-3362](tel:513-559-3362)

Email: Leksi.travitz@uc.edu

Manish Anand

Baylor Scott and White Research

Recruiting

Temple,Texas,76502,United States

Michell Trevino

Phone: [254-935-5838](tel:254-935-5838)

Email: michelle.trevino1@bswhealth.org

Mohanram Narayanan

University of California Irvine

Recruiting

Orange,California,92868,United States

Kelly Acero

Email: kacero@hs.uci.edu

Sheetal Desai

NY Nephrology

Recruiting

Clifton Park,New York,12065,United States

Frank Cortazar

Howard Phelan

Phone: [518-579-0017](tel:518-579-0017)

Email: howard.phelan@nyneph.com

Uni Wisconsin School Med Pub Health

Recruiting

Madison,Wisconsin,53792,United States

Tripti Singh

Wayne State University

Recruiting

Detroit, Michigan, 48201, United States

Yahya Osman

Yanni Zhuang

Phone: 313-745-7371

Email: yzhuang@med.wayne.edu

Emory University School of Medicine

Recruiting

Atlanta, Georgia, 30303, United States

Hilton Mozee

Phone: 404-616-4440

Email: hmozee@emory.edu

S Sam Lim

Hospital for Special Surgery

Recruiting

New York, New York, 10021, United States

Haley Slosberg

Phone: 212-606-1728

Email: slosbergh@hss.edu

Kyriakos Kirou

University of California San Diego

Recruiting

San Diego, California, 92037, United States

Kenneth Carekin Kalunian

Linda Mendoza

Phone: +1 858 534 2555

Email: lmendoza@health.ucsd.edu

University of Kansas Hospital

Recruiting

Kansas City,Kansas,66160,United States

Phone: 913-588-0053

Kelly Liang

Univ of Pennsylvania Medical Center

Recruiting

Philadelphia,Pennsylvania,19104,United States

Gaia Coppock

Radhakrishna Kallem

Email: Krishna.Kallem@pennmedicine.upenn.edu

UC Davis School of Medicine

Recruiting

Sacramento,California,95817,United States

Morgan Balaban

Email: mbalaban@ucdavis.edu

Nasim Wiegley

Northern Assoc of Northern VA

Recruiting

Fairfax,Virginia,22033,United States

Phone: 703-953-0155

Gregory Wang

University Of Alabama

Recruiting

Birmingham,Alabama,35294,United States

Jane Vines

Email: jsnowden@uabmc.edu

José Mosquera Rubin

Liberty Research Center

Recruiting

Dallas,Texas,75230,United States

Irfan Agha

Laurie Jones

Phone: 972-274-5555

Email: laurie.jones@usoncology.com

VA NM Healthcare System

Recruiting

Albuquerque,New Mexico,87108,United States

Anthony Sedillo

Phone: 505-265-1711

Email: anthony.sedillo@va.gov

Kavitha Ganta

Arthritis and Rheumatology Ins

Recruiting

Allen,Texas,75013,United States

Kiran Khandelwal

Email: k.khandelwal@dfwarthritis.com

Megha Patel Banker

Fides Clinical Research

Recruiting

Atlanta,Georgia,30342,United States

Dillon Ha

Phone: 404-252-0256

Email: dha@fidesclinicalresearch.com

Elizabeth Nguyen

Northwell Health

Recruiting

New York, New York, 10028, United States

Justina D Costa

Phone: [516-708-2550](tel:516-708-2550)

Email: jdcosta@northwell.edu

Richard Furie

Sahni Rheumatology and Therapy

Recruiting

West Long Branch, New Jersey, 07764, United States

Kiren Sahni

Michael J Harris

Phone: [732-272-1456](tel:732-272-1456)

Email: m.harris@sahnirheumatology.com

UMC New Orleans

Recruiting

New Orleans, Louisiana, 70112, United States

Madeline Young

Email: madeline.young@lcmchealth.org

Stephen Lindsey

Univof Texas Southwestern Med Cntr

Recruiting

Dallas, Texas, 75235, United States

David Karp

Vietnam

Novartis Investigative Site

Recruiting

Hanoi, 100000, Vietnam

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: [+41613241111](tel:+41613241111)

Email:

Novartis Pharmaceuticals

Phone: [1-888-669-6682](tel:1-888-669-6682)

Email: novartis.email@novartis.com

Source URL: <https://prod1.novartis.com/clinicaltrials/study/nct05126277>

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT05126277>
2. [#trial-eligibility](#)
3. <tel:+17185849000#6667>
4. <mailto:olga.andriunas@va.gov>
5. <tel:409-772-1062>
6. <mailto:sttsimmo@utmb.edu>
7. <tel:858-401-7205>
8. <mailto:Jaqueline.X.GomezSolis@kp.org>
9. <tel:+17709621616#8334>
10. <tel:210-617-5111>
11. <tel:310-825-9447>
12. <mailto:LSahakian@mednet.ucla.edu>
13. <tel:305-243-2568>
14. <mailto:pdm73@med.miami.edu>
15. <mailto:katherin.mendez@unlv.edu>
16. <tel:972-299-8399>
17. <mailto:ashwinboda@pccrsolutions.com>
18. <tel:904-953-2451>
19. <mailto:Thomas.Carolyne@mayo.edu>
20. <tel:513-559-3362>
21. <mailto:Leksi.travitz@uc.edu>
22. <tel:254-935-5838>
23. <mailto:michelle.trevino1@bswhealth.org>
24. <mailto:kacero@hs.uci.edu>
25. <tel:518-579-0017>
26. <mailto:howard.phelan@nyneph.com>
27. <tel:313-745-7371>
28. <mailto:yzhuang@med.wayne.edu>
29. <tel:404-616-4440>
30. <mailto:hmozee@emory.edu>
31. <tel:212-606-1728>
32. <mailto:slosbergh@hss.edu>
33. <tel:+18585342555>
34. <mailto:lnmendoza@health.ucsd.edu>
35. <tel:913-588-0053>
36. <mailto:Krishna.Kallem@pennmedicine.upenn.edu>
37. <mailto:mbalaban@ucdavis.edu>

38. tel:703-953-0155
39. mailto:jsnowden@uabmc.edu
40. tel:972-274-5555
41. mailto:laurie.jones@usoncology.com
42. tel:505-265-1711
43. mailto:anthony.sedillo@va.gov
44. mailto:k.khandelwal@dfwarthritis.com
45. tel:404-252-0256
46. mailto:dha@fidesclinicalresearch.com
47. tel:516-708-2550
48. mailto:jdcosta@northwell.edu
49. tel:732-272-1456
50. mailto:m.harris@sahnirheumatology.com
51. mailto:madeline.young@lcmchealth.org
52. tel:+41613241111
53. mailto:
54. tel:1-888-669-6682
55. mailto:novartis.email@novartis.com